Efficacy and Safety of Zhenwu Decoction in the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis

Table 2

Details of the included studies.

No.	Authors, publication year	Sample sizes (M/F)	Mean age (years)	Duration (months)	Intervention		Adverse events	Outcomes
					Experimental group	Control group
1	Zhang et al. 2021 [12]	E:23/22 C:24/21	E:67.9 ± 10.1 C:67.6 ± 10.3	2	ZWD + C	Hypoglycemic drugs	Not mentioned	①②
2	Yu 2021 [13]	E:31/19 C:33/17	E:57.94 ± 8.87; C:58.21 ± 8.66	1	ZWD + C	INS	Not mentioned	①②④⑤
3	Zhang 2020 [14]	E:18/15; C:17/16	E:54.8 ± 4.5; C:54.6 ± 4.2	1	ZWD + C	Hypoglycemic drugs/INS	Not found	①②④⑥
4	Fan 2018 [15]	E:40/30; C:38/32	E:63.57 ± 4.25; C:63.26 ± 4.33	2	ZWD + C	Hypoglycemic drugs/INS	Not mentioned	①②③④⑥
5	Sun 2017 [16]	E:68/62; C:64/66	E:46.82 ± 7.65; C:45.69 ± 7.26	1	ZWD + C	Hypoglycemic drugs/INS	Not found	①②④⑤⑥
6	Zhu 2016 [17]	E:19/16; C:18/17	E:58.4 ± 5.5; C:58.5 ± 5.6	1	ZWD + C	Hypoglycemic drugs/INS	Not mentioned	①②⑤
7	Hu et al. 2012 [18]	E:24/10; C:22/12	E:46.5 ± 10.8; C:47.8 ± 12.3	1	ZWD + C	INS	Not mentioned	①②⑤⑥
8	Zhang 2010 [19]	E:25/20; C:23/17	Not mentioned	1	ZWD + C	INS	Not mentioned	①②⑤
9	Ya and wang 2008 [20]	E:30; C:30 (39/21)	36–66	2	ZWD + C	Hypoglycemic drugs + hypotensor (captopril)	Not mentioned	①②③④⑥
10	Lan et al. 2006 [21]	E:13/17; C:14/16	18–65	2	ZWD + C	Hypoglycemic drugs + hypotensor (captopril)	Not mentioned	①③④⑥
11	Liu and Hu 2020 [22]	E:36/14; C:35/15	E:57.35 ± 8.77; C: 56.37 ± 9.12	1	ZWD + C	INS	Not mentioned	①②⑤
12	Liu 2017 [23]	E:49/43; C:40/52	E:49.5 ± 17.5; C:53.5 ± 18.5	1	ZWD + C	CWM	Not mentioned	①②④⑥
13	Xie 2021 [24]	E:19/13	E:51.32 ± 2.15; C:51.26 ± 2.28	1	ZWD + C	Hypotensor (losartan)	Not mentioned	①②③④⑥

① Total effective rate ② fasting blood glucose (FBG) ③ blood urea nitrogen (BUN) ④ 24h urine protein ⑤ creatinine clearance (Ccr) ⑥ serum creatinine (Scr) ZWD: ZhenWu decoction C: control group INS: insulin CWM: conventional Western medicine.